CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer
Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies (LUMOS2)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
SLIDE-HCC: Phase II trial of STRIDE (durvalumab + tremelimumab) + lenvatinib vs STRIDE in patients with unresectable hepatocellular carcinoma
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Docetaxel and Hormone Treatment compared to Hormone Treatment alone in people with Metastatic Castration Sensitive Prostate Cancer and Less than Optimal PSA Response (TRIPLE-SWITCH)
These CCTG trials have been formally permanently closed/terminated. No further ethics approvals or folow up data are required, more information can be found on the CCTG website under the "Toolbox".
CCTG trials BL13 and IND237 have been centrally activated with further information please visit the trial pages.
Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy. Trials currently under CCTG's DSMC oversight include:
This is a reminder to obscure all personal identifiers of participants from reports and correspondence sent to CCTG and to provide an update on our privacy breach process. The Canadian Cancer Trials Group has recently sent an email to Centre Representatives and Contact Clinical Research Associates on December 21, 2018 outlining how to prevent a privacy breach and what to expect if one occurs.
Congratulations to Professor Janette Vardy (University of Sydney) and Doctor Haryana Dhillon (University of Sydney) who were successful in their funding application to the National Health and Medical Research Council (NHMRC) to continue the CCTG led CHALLENGE (CO.21) trial in Australia
The results of the Unicancer and the Canadian Cancer Trials Group (CCTG) PRODIGE 24 | CCTG PA.6 study have been published in the New England Journal of Medicine. The practice changing results indicate a significant improvement in the survival of pancreatic cancer patients treated with the mFOLFIRINOX chemotherapy compared to the current standard treatment with gemcitabine
As we embark on a new year, it is time to reflect on what we have accomplished together this year and what 2019 will bring. It has been a busy year with continued growth and expansion across our national and international networks.
Congratulations to the researchers who presented abstracts at the American Society of Hematology Annual Meeting (ASH) and San Antonio Breast Cancer Symposium.
